Literature DB >> 668794

Effects of various cephalosporins on the proximal tubule of the human kidney.

A W Mondorf, M Zegelman, J Klose, L Maske, J E Scherberich, T Stefanescu, H Müller, W Schoeppe.   

Abstract

Cephamandol 6.0 g, cephazolin 6.0 g or cephacetrile or cephalothin 8.0 g were administered as short-term infusions on 3 consecutive days to informed volunteers, who had no history or evidence of impairment of renal function. There were 15 subjects in the cephamandol, cephacetrile and cephalothin groups and 14 subjects in the cephazolin group. Alanine-aminopeptidase, a characteristic tubule enzyme, was determined in a 24-hour urine 2 days before administration, during the 3 day administration and on the 4 subsequent days. In addition, alanine-aminopeptidase was also estimated immunologically in concentrated urine with the aid of an anti-brush border antibody. Cephamandol, cephazolin and cephalothin were completely without effect on the proximal tubule. Cephacetrile, on the other hand, showed clear reactions in 9 out of 15 subjects, in the form of elevated AAP activity in urine and in 6 of the cases membrane elimination was demonstrable immunologically. After withdrawal of the medication, the values of the responder group returned spontaneously to normal, i.e. no cumulative effect was detected. These investigations show that elimination of alanine-aminopeptidase in the urine is a very sensitive index of the action of cephalosporins on renal tubules.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 668794     DOI: 10.1007/BF00644609

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  34 in total

1.  Nephrotoxicity of combined cephalothin-gentamicin regimen.

Authors:  F Cabanillas; R C Burgos; C Rodríguez; C Baldizón
Journal:  Arch Intern Med       Date:  1975-06

2.  Nephrotoxicity associated with cephalothin administration.

Authors:  P C Carling; B A Idelson; A A Casano; E A Alexander; W R McCabe
Journal:  Arch Intern Med       Date:  1975-06

3.  [Indications and dangers of combined cephalothin-gentamicin therapy].

Authors:  W Stille
Journal:  Adv Clin Pharmacol       Date:  1974

4.  Acute renal failure during cephalothin therapy.

Authors:  J R Burton; N S Lichtenstein; R B Colvin; N E Hyslop
Journal:  JAMA       Date:  1974-08-05       Impact factor: 56.272

5.  Acute renal failure after high doses of gentamicin and cephalothin.

Authors:  P Noone; J R Pattison; M S Shafi
Journal:  Lancet       Date:  1973-06-16       Impact factor: 79.321

6.  [Combined cephalothin-gentamicin therapy of severe urologic infections].

Authors:  P Falge; A Hofstetter; G Staehler
Journal:  Med Welt       Date:  1973-03-09

7.  [Acute renal failure during treatment with gentamicin and cephalothin].

Authors:  D Kleinknecht; P Jungers
Journal:  Nouv Presse Med       Date:  1973-01-06

8.  [Acute renal failure following gentamicin-cephalosporin association therapy].

Authors:  A Opitz; I Herrmann; D van Herrath; K Schaefer
Journal:  Med Welt       Date:  1971-03-13

9.  Failure to demonstrate nephrotoxicity of cephalothin in rabbits with reduced renal function.

Authors:  R C Venuto; J H Stein; T F Ferris
Journal:  Proc Soc Exp Biol Med       Date:  1972-03

10.  [Alanine aminopeptidase and creatinine excretion under various conditions of diuresis in man].

Authors:  U Burchardt; A Hempel; J B Höpfner; R D Hempel
Journal:  Z Gesamte Inn Med       Date:  1976-07-15
View more
  3 in total

1.  Human pharmacology of cefotaxime (HR 756), a new cephalosporin.

Authors:  R Lüthy; R Münch; J Blaser; H Bhend; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

2.  Tobramycin nephrotoxicity: failure of cefotaxime to potentiate renal toxicity.

Authors:  J Kuhlmann; G Seidel; H Grötsch
Journal:  Infection       Date:  1982       Impact factor: 3.553

3.  Assessment of the nephrotoxic potential of ceftazidime and a ceftazidime/tobramycin combination in volunteers.

Authors:  A W Mondorf; F T Heynold; J E Scherberich; H Hess; W Schoeppe
Journal:  Infection       Date:  1983       Impact factor: 3.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.